Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
This bill amends 21 U.S.C. 823(h) to allow the Attorney General, in consultation with the Secretary, to separately register qualified practitioners to prescribe methadone for opioid use disorder to be dispensed by pharmacies. Prescriptions must be electronic, for liquid or dispersible tablet formulations, and comply with federal and state dispensing quantity limits.
Progressives emphasize expanded access and harm reduction benefits
Relative to its intended legislative type, this bill makes a clear, substantive statutory change to expand methadone access by authorizing separate practitioner registration and pharmacy dispensing, and it builds in specific practitioner qualifications, prescribing/dispensing requirements, and reporting metrics.
This bill amends 21 U.S.C. 823(h) to allow the Attorney General, in consultation with the Secretary, to separately register qualified practitioners to prescribe methadone for opioid use disorder to be dispensed by pharmacies.
Prescriptions must be electronic, for liquid or dispersible tablet formulations, and comply with federal and state dispensing quantity limits.
The bill permits telemedicine delivery, requires informed consent including confidentiality differences versus opioid treatment programs, allows States to request cessation of registrations, removes a pharmacy registration requirement for dispensing such prescriptions, and mandates annual DEA reporting.
Technically focused expansion of OUD treatment has bipartisan appeal but alters entrenched methadone rules and may trigger regulatory and stakeholder pushback.
Relative to its intended legislative type, this bill makes a clear, substantive statutory change to expand methadone access by authorizing separate practitioner registration and pharmacy dispensing, and it builds in specific practitioner qualifications, prescribing/dispensing requirements, and reporting metrics.
Progressives emphasize expanded access and harm reduction benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize expanded access and harm reduction benefits
Generally supportive; views the bill as a harm-reduction measure that broadens access to methadone treatment outside highly regulated opioid treatment programs.
Appreciates telemedicine and pharmacy-based dispensing but wants stronger protections for equity, clinician scope, and confidentiality.
Cautiously favorable if safeguards function; sees the bill as a practical expansion that balances access with practitioner standards and a State opt-out.
Wants clear implementation plans, oversight metrics, and funding for training and monitoring.
Skeptical or opposed; views broad pharmacy dispensing of methadone as increasing diversion risk and federal overreach into controlled-substance regulation.
May accept provisions like limited prescriber qualifications and State opt-out, but remains concerned about public safety and enforcement.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically focused expansion of OUD treatment has bipartisan appeal but alters entrenched methadone rules and may trigger regulatory and stakeholder pushback.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize expanded access and harm reduction benefits
Technically focused expansion of OUD treatment has bipartisan appeal but alters entrenched methadone rules and may trigger regulatory and s…
Relative to its intended legislative type, this bill makes a clear, substantive statutory change to expand methadone access by authorizing separate practitioner registration and pharmacy dispensing, and it builds in spe…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.